申请人:Takeda Chemical Industries, Ltd.
公开号:US04518602A1
公开(公告)日:1985-05-21
Novel compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group; R.sup.2 is a phenyl, thienyl, furyl, naphthyl, benzothienyl or pyridyl group which may have as a substituent a lower alkoxy, a lower alkyl, a halogen, trifluoromethyl, a lower alkenyl or methylenedioxy; R.sup.3 is hydrogen, benzyl or a lower alkyl; one of R.sup.4 and R.sup.5 is hydrogen or a lower alkyl, and the other is an aryloxy, or lower aliphatic hydrocarbon, an alicyclic hydrocarbon having not more than 6 carbon atoms or an aromatic group which may have a substituent, or a group represented by the formula, --S(O).sub.m --R.sup.6 (in which R.sup.6 is phenyl or a lower alkyl group; m is an integer of 0 to 2), or R.sup.4 and R.sup.5 each combine with the other to represent one alkylene group; n is an integer of 2 to 6, or a pharmaceutically acceptable salt thereof has a selective inhibitory action on bio-synthesis of thromboxane A.sub.2 (TXA.sub.2) and an effect of enhancing the production of prostaglandin I.sub.2 (PGI.sub.2), and can be used in mammals for to prevention and treatment of arterial thrombosis caused by platelet aggregation or ischemic diseases caused by vasospasms in cardiac, cerebral and peripheral circulatory system (e.g. cardian infarction, apoplexy, infarct of blood vessels in kidney, lung and other organs, pectic ulcer, etc.).
式(I)的新化合物:##STR1## 其中R1是吡啶基团;R2是苯基、噻吩基、呋喃基、萘基、苯并噻吩基或吡啶基团,其上可带有取代基,如低级烷氧基、低级烷基、卤素、三氟甲基、低级链烯基或亚甲二氧基;R3是氢、苄基或低级烷基;R4和R5中之一是氢或低级烷基,另一是芳氧基、低级脂肪族烃、不超过6个碳原子的脂环烃或芳香基团,该芳香基团可带有取代基,或由式--S(O)m--R6表示的基团(其中R6是苯基或低级烷基团;m是0至2的整数),或者R4和R5各自与其他基团结合形成一个亚烷基团;n是2至6的整数,或其药学上可接受的盐,具有选择性抑制血栓素A2(TXA2)生物合成和增强前列环素I2(PGI2)产生的作用,可用于哺乳动物预防和治疗由血小板聚集引起的动脉血栓形成或由血管痉挛引起的心脏、脑和外周循环系统的缺血性疾病(例如心肌梗死、中风、肾脏、肺和其他器官的血管梗死、消化性溃疡等)。